Formycon AG (LON:0W4N)

Market Cap	311.38M -12.5%
Revenue (ttm)	52.73M +18.3%
Net Income	-21.64M
EPS	-1.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	86.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	20.30
Previous Close	20.60
Day's Range	20.30 - 20.65
52-Week Range	15.90 - 26.85
Beta	0.72
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 196
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0W4N

Financial Performance

In 2025, Formycon AG's revenue was 44.48 million, a decrease of -36.17% compared to the previous year's 69.67 million. Losses were -64.70 million, -48.52% less than in 2024.

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 7, 2026

Data Sources Report a data error